Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
1 A. H5 _7 C$ \1 H k* `NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
/ P* @" c1 I* J- `; ~" y+ Author Affiliations
$ w% I+ o& R; }) j7 b8 w. V: F4 P, @5 V3 y" j+ N; L
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
6 U! n4 c+ C7 C2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
$ Y" ~/ a! A( [3 F+ k. ~3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 3 D0 q4 A% L( B" l" C' _8 f
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan , W; L" ^, z4 c0 N2 u
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
& m0 b* K* I: L7 l" D6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
9 L4 _4 H6 `; q# W% Q) i9 L7Kinki University School of Medicine, Osaka 589-8511, Japan
, [8 @& g. _( A9 b' U( m: C; m8Izumi Municipal Hospital, Osaka 594-0071, Japan
7 t2 E- ~6 E; E9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
( ?0 ` g, e. d N- nCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 7 E- ?' n; l k7 v, l
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
l) F% @- Z2 I! N9 o! w6 W
2 E/ v! p! o- x4 h9 H: Y3 D |